Expression of CD90/EpCAM/CD24 in hepatocellular carcinoma cell lines at various stages of differentiation / 中华肝脏病杂志

<p><b>OBJECTIVE</b>To confirm the malignant phenotype of hepatocarcinoma cell (HCC) lines at various stages of differentiation (MHCC97L, MHCC97H and HCCLM3) and to explore their expression levels of cancer stem cell (CSC) markers.</p><p><b>METHODS</b>The invasive and proliferative properties of each HCC line were assessed by transwell assay and the Cell Counting Kit-8 (CCK-8) colorimetric assay. Sensitivity to chemotherapy was assessed by treatment with oxaliplatin and determination of the half inhibitory concentration (IC50). The expression of CD90, EpCAM and CD24 was measured by flow cytometry.</p><p><b>RESULTS</b>The number of cells that migrated through the invasion assay membrane were significantly different between the three HCC lines: HCCLM3 (30.57 +/- 8.95) more than MHCC97H (21.33 +/- 4.17) more than HCC97L (9.33 +/- 3.85), P less than 0.01. The IC50 was significantly different between the three HCC lines: HCCLM3 (36.57 +/- 6.95) mumol/L more than MHCC97H (26.35+/-3.88) mumol/L more than MHCC97L (17.68 +/- 3.25) mumol/L. The CSC marker with the highest expression on all three HCC lines was CD90 (HCCLM3: 0.92% +/- 0.21%, MHCC97H: 1.98% +/- 0.23%, and MHCC97L: 2.55% +/- 0.34%), followed by EpCAM (2.11% +/- 0.32%, 3.23% +/- 0.18%, and 4.38% +/-0.49%, respectively), and CD24 as the lowest (0.68% +/- 0.37%, 1.22% +/- 0.26%, and 1.36% +/- 0.24%, respectively).</p><p><b>CONCLUSION</b>Higher expression of CSC markers on HCC lines is associated with a stronger invasive ability and higher sensitivity to chemotherapy.</p>

Effect of splenectomy on implanted hepatic tumor rat model with portal hypertension / 第二军医大学学报

Objective To evaluate the effect of splenectomy on development and progression of implanted hepatic tumors by establishing implanted hepatic tumor rat model with portal hypertension. Methods Rat cirrhosis with portal hypertension models were built by subcutaneous injection of carbon tetrachloride, and then the rats were randomly divided into two groups. Group A was subjected to splenectomy and implantation of Walker-256 tumor tissue on the left lobe of liver, and group B was only subjected to implantation of tumor tissue. T-lymphocyte subsets CD4, CD8 and CD4/CD8 of two groups were examined 10 days after implantation of tumor tissue; the left lobe of liver was resected and the maximal tumor size was measured; expression of Ki-67 was detected by immunohistochemical method in the tumor tissues. Results The results of blood routine test and liver function test were obviously abnormal in rat model of portal hypertension. The levels of CD4 and CD4/CD8 in group A were higher than those in group B (0.36±0.01 vs 0.35±0.02,1.33±0.08 vs 1.24±0.05; P<0.05 or P<0.01), and the level of CD8 in group A was lower than that of CD8 in group B (0.27±0.01 vs 0.29±0.02, P<0.01). There was no significant difference in the diameter of hepatic tumor between the two groups. Ki-67-positive rate of tumor in group A was lower than that in group B (P<0.05). Conclusion Splenectomy in portal hypertension rats can not only help to improve the immunity against hepatic tumor, but also decrease the invasive ability of the hepatic tumor to some extent.